Relatlimab–nivolumab: A practical overview for dermatologists
Author:
Publisher
Elsevier BV
Subject
Dermatology
Reference16 articles.
1. Neoadjuvant relatlimab and nivolumab in resectable melanoma;Amaria;Nature,2022
2. Preclinical characterization of relatlimab, a human LAG-3-blocking antibody, alone or in combination with nivolumab;Thudium;Cancer Immunol Res,2022
3. RELATIVITY-047 investigators. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma;Tawbi;N Engl J Med,2022
4. Nivolumab/relatlimab: a novel addition to immune checkpoint inhibitor therapy in unresectable or metastatic melanoma;Phillips;Ann Pharmacother,2023
5. Relatlimab plus nivolumab beneficial for previously untreated metastatic or unresectable melanoma;O'Rourke;Cancer,2022
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Treatment of malignant melanoma with coxsackievirus A21 (V937): An emerging oncolytic virotherapy;Experimental Dermatology;2024-08-29
2. Immunotherapy revolutionizing brain metastatic cancer treatment: personalized strategies for transformative outcomes;Frontiers in Immunology;2024-07-29
3. Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy;Basic Research in Cardiology;2024-07-22
4. Unraveling the complex interplay between anti-tumor immune response and autoimmunity mediated by B cells and autoantibodies in the era of anti-checkpoint monoclonal antibody therapies;Frontiers in Immunology;2024-01-22
5. Nivolumab/Relatlimab-rmbw: A Novel Dual Combination Therapy to Treat Adult and Pediatric Patients With Unresectable or Metastatic Melanoma;American Journal of Therapeutics;2023-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3